This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cima Labs Sues aaiPharma

Updated from 12:13 p.m. EDT

It seems that aaiPharma (AAII) cannot get away from the big deal that got away.

The Wilmington, N.C.-based drug company has been sued by Cima Labs (CIMA), which is seeking to recover the $11.5 million break-up fee it paid to aaiPharma after Cima called off their merger last year.

Cima also wants at least $5 million in damages, arguing that aaiPharma misled Cima and investors about its financial health.

Cima eventually agreed to be acquired by Cephalon, (CEPH) of West Chester, Pa., in a deal that was finally approved by the Federal Trade Commission on Monday. The transaction, in which Cima shareholders received $34 a share, closed late Thursday afternoon, making Cima a wholly-owned subsidiary of Cephalon.

Cima's lawsuit was announced Wednesday, a few days after aaiPharma revealed that a Cima representative had inquired about getting a refund on the breakup fee. In its latest 10-Q filing, aaiPharma said it would keep the money and fight any lawsuit.

Cima, based in Eden Prairie, Minn., filed suit in Hennepin County District Court, accusing aaiPharma of fraud and breach of contract relating to the merger agreement they signed 12 months ago. After Cima accepted Cephalon's offer in November, Cima paid the break-up fee to aaiPharma.

Cima bases its complaint on revelations by aaiPharma that have provoked investigations from the Securities and Exchange Commission and the Justice Department about aaiPharma's product-selling and accounting practices. The company recently restated earnings reports for 2002 and 2003.

Cima's lawsuit alleges that it never would have considered a merger if it had known about aaiPharma's true financial condition. In addition to the $11.5 million break-up fee, Cima said it wants more than $5 million in expenses and fees related to its evaluation and negotiation of aaiPharma's offer.

"Had aaiPharma's financial results as restated been public, we would not have entered into a merger agreement with the company," Steven B. Ratoff, Cima's chairman, said Wednesday. "Under the circumstances, we believe it is appropriate to seek recovery of the break-up fee and recoup the significant fees and expenses we incurred in connection with negotiating the transaction."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs